Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A chronic communicable infection which is a principal or polar form of leprosy. This disorder is caused by mycobacterium leprae and produces diffuse granulomatous skin lesions in the form of nodules, macules, or papules. The peripheral nerves are involved symmetrically and neural sequelae occur in the advanced stage.
Biomarker and diagnostic research for lepromatous leprosy has been reported in the published literature.
1 FDA-approved treatment is available for lepromatous leprosy, including lamprene (LAMPRENE, approved 1986). An additional 1 compound holds orphan drug designation.
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
146 publications have been identified in PubMed for lepromatous leprosy. Research spans Case Report / Case Series (59%), Review / Meta-Analysis (10%), and Basic Science / Preclinical (10%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 86 | 59% |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 4:12 AM UTC
LAMPRENE
— |
— |
1986 |
Available |
The following drugs have received orphan drug designation from the FDA for lepromatous leprosy. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor | Designated | Exclusivity End | Designation Status |
|---|---|---|---|---|---|
Lamprene | Clofazimine | Novartis Pharmaceutical Corporation | 1984 | 1993 | Designated (drug approved for other indication) |
Gene therapy approaches for lepromatous leprosy have been reported in the published literature.
1 trial found
Research summaries |
15 |
10% |
Laboratory research | 14 | 10% |
Testing and diagnosis research | 12 | 8% |
Disease patterns and progression | 9 | 6% |
Clinical study results | 7 | 5% |
Other research | 2 | 1% |
New treatment approaches | 1 | 1% |
Kruthof J (2026). [PMID: 41512549](https://pubmed.ncbi.nlm.nih.gov/41512549/). *International journal of obstetric anesthesia*. [Case Report / Case Series]
Adil M (2026). [PMID: 41655090](https://pubmed.ncbi.nlm.nih.gov/41655090/). *Indian journal of dermatology, venereology and leprology*. [Case Report / Case Series]
Joshi RP (2026). [PMID: 41128716](https://pubmed.ncbi.nlm.nih.gov/41128716/). *The American Journal of dermatopathology*. [Case Report / Case Series]
Villanueva CAG (2026). [PMID: 41777484](https://pubmed.ncbi.nlm.nih.gov/41777484/). *Respirology case reports*. [Case Report / Case Series]
Subramanian KS (2026). [PMID: 41884721](https://pubmed.ncbi.nlm.nih.gov/41884721/). *Indian journal of dermatology*. [Clinical Trial Publication]
Khadka A (2026). [PMID: 41531684](https://pubmed.ncbi.nlm.nih.gov/41531684/). *Clinical case reports*. [Case Report / Case Series]
da Silva GG (2026). [PMID: 41580618](https://pubmed.ncbi.nlm.nih.gov/41580618/). *BMC infectious diseases*. [Basic Science / Preclinical]
Singh M (2026). [PMID: 41894630](https://pubmed.ncbi.nlm.nih.gov/41894630/). *International journal of mycobacteriology*. [Case Report / Case Series]
Zhang Y (2026). [PMID: 41848485](https://pubmed.ncbi.nlm.nih.gov/41848485/). *Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG*. [Case Report / Case Series]
Soares CT (2026). [PMID: 40662219](https://pubmed.ncbi.nlm.nih.gov/40662219/). *Histology and histopathology*. [Diagnostic / Biomarker]
AI-curated news mentioning lepromatous leprosy
Updated Jun 5, 2026
A case report details lepromatous leprosy in a non-endemic setting, highlighting chronic painless ulcers and inflammatory arthropathy. This study contributes to understanding the disease's presentation outside typical regions.